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e under thebstract Objective: To examine the patterns of antituberculous drug resistance of
Mycobacterium tuberculosis in patients with pulmonary and extra-pulmonary tuber-
culosis in the Eastern province of the Kingdom of Saudi Arabia.
Methods: This is a retrospective study of antibiotic susceptibility of 1681 non-
repetitive M. tuberculosis isolates from 1/2003 to 6/2010.
Results: Of the total patients, 41% (n = 687) were Saudis and 59% (n = 994) were
non-Saudis. The pulmonary and extra-pulmonary specimens constituted 68%
(n = 1148) and 32% (n = 533), respectively. The incidence of resistance was 15.5%
to one or more of anti-tuberculosis drugs. The resistance rates to first-line drugs
were as follows: streptomycin (10.4%), INH (9.8%), rifampicin (1.5%) and ethambutol
(1.0%). Multi-drug resistant tuberculosis was present in 1.4% (n = 24) of the sample.
Conclusion: INH resistance in this studywas relatively high,whereas the rateofMDR-
TB was low. A rate of MDR-TB observed in this study was 1.4%. Thus, an empiric four-
drug therapy is required to treat patients with tuberculosis in this area of Saudi Arabia.
ª 2011 Ministry of Health, Saudi Arabia. Published by Elsevier Ltd. This is an open
access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/
by-nc-nd/4.0/).1
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Tuberculosis (TB) is one of the oldest diseases
known to man and remains a major health problem
throughout the world; it is a major cause of mor-
bidity and mortality. According to the Centers for
Disease Control and prevention (CDC), TB inci-
dence in the United States reached 13,767 cases
in 2006 with a 3.2% decline from 2005 [1]. The inci-
dence of TB in 2006 was the lowest recorded rate
since 1953; however, the rate of decline has slo-
wed since 2000 [1]. An initial reversal of downward
trend was attributed to the AIDS epidemic, the
emergence of drug resistance, and the involvement
of foreign-born persons and racial/ethnic minority
populations [2–4]. In India – the largest populated
country of the world – HIV epidemic has also con-
tributed to increased incidence of drug resistance
[5]. Drug resistance of Mycobacterium tuberculosis
showed marked geographic variation from one
country to the other. The latest reported global
rates of single-drug resistance tuberculosis (SDR-
TB) ranged from 1.6% to 33.3% [6]. In Saudi Arabia
the pattern of M. tuberculosis resistance is also
dependent on the region of reporting. The range
of drug resistance rates against isoniazid reported
from various regions of Saudi Arabia has been
3.4–19.4% in Riyadh (central region), 10.3–28% in
Jeddah (western pilgrims hub), 41% in Jizan (near
Yemen border), 6.5% in Taif and 6–12.5% in Dam-
mam eastern area; resistance rates against rifam-
picin has been 9% in Riyadh, 5.1–23.4% in
Jeddah; 15.3% in Taif; 20% in Jizan and 0.2–7.5%
in Dammam area. Rates of MDR-TB ranged between
3.7% and 11.85% in Riyadh; 44% in Jizan and 0.7–6%
in Dammam area [7–10]. There has been no recent
large-scale sequential study on this topic in Saudi
Arabia. Thus, this retrospective study was under-
taken in the Eastern province of Saudi Arabia for
a period of seven sequential years from 2003 to
2010.
2. Materials and methods
The regional laboratory and blood bank of Dam-
mam medical complex received various specimens
for TB culture from different centers in the Eastern
province. These specimens included sputum, pleu-
ral fluid, pericardial fluid, ascitic fluid, cerebrospi-
nal fluid, urine, and fine needle aspiration and
tissue biopsies. Specimens were processed for
acid-fast bacilli smear (AFB) using Ziehl–Neelsen
stain, and were processed for M. tuberculosis cul-
tures and susceptibility to first-line anti-TB drugs.
All specimens were processed according to thespecimen type. Sputum and other respiratory spec-
imens were decontaminated and concentrated by
NALC–NAOH method. Sterile body fluids were cen-
trifuged and deposit was used for the culture. Cul-
ture and susceptibility testing was done using MGIT
medium and BACTEC MGIT 960 instrument (Becton,
Dickinson and Company, 7 Loveton Circle, Sparks,
Maryland 21152, USA) [11]. MGIT media consisted
of Middle Brooke medium with PANTA (antibiotic
mixture) and growth supplement. After inoculation
tubes were introduced into the BACTEC MGIT 960
instrument and were kept as recommended for
42 days protocol, identification of M. tuberculosis
complex (M. tuberculosis, Mycobacterium bovis,
Mycobacterium africanum, Mycobacterium micro-
oti) was done by probetec instrument using probe-
tec ET CTB kit (Becton, Dickinson and Company, 7
Loveton Circle, Sparks, Maryland 21152, USA) [11].
Antibiotic susceptibility testing for rifampicin,
streptomycin, INH, and ethambutol was done by
BACTEC MGIT 960 AST system. A modified Middle-
Brook 7H9 Broth, which supports the growth and
detection of mycobacterium, was used for suscep-
tibility testing. The critical concentrations of these
drugs were as follows: streptomycin 1.0 lg/ml, INH
0.1 lg/ml, rifampicin 1 lg/ml, and ethambutol
5 lg/ml. A strain which showed growth of 1% or
more at critical concentration was identified as
resistant (BACTEC MGIT 960 AST system Users Man-
ual) [12]. M. tuberculosis strain resistant in vitro to
both INH and rifampicin was considered multi-drug
resistant (Becton, Dickinson, Sparks, MD, USA, BD
diagnostics-DST Liquid Media Product and Proce-
dure Manual) [13].
3. Results
During the study period, a total of 1681 non-repet-
itive M. tuberculosis isolates were included. Saudis
constituted 41% (n = 687), while 59% (n = 994) were
non-Saudis. Male to female ratio in Saudi patients
was 43% (n = 296) to 57% (n = 391). In non-Saudis
there was a male predominance with 71%
(n = 703) being males and 29% (n = 291) females.
M. tuberculosis isolates were obtained from pul-
monary specimens 68.3% (n = 1148) and 31.7%
(n = 533) were of extra-pulmonary origin (Table 1).
The incidence of resistance to any one antitu-
berculous drug was 15.5%. However, resistance
rates to individual drugs were as follows: strepto-
mycin (10.4%), INH (9.8%), rifampicin (1.5%) and
ethambutol (1.0%), respectively (Table 1). Compar-
ing Saudis and non-Saudi patients, there was no
statistically significant difference in the resistance
rate to single-line agents (Table 1). Drug resistance
Table 2 Extra-pulmonary vs. pulmonary tuberculosis.
Extra-pulmonary Pulmonary p-Value
Streptomycin 41 (7.7%) 134 (11.7%) 0.036
INH 58 (10.9%) 106 (9.2%) 0.165
Rifampicin 7 (1.3%) 19 (1.7%) 0.67
Ethambutol 2 (0.4%) 15 (1.3%) 0.178
Saudi:non-Saudi 266:267
49.9:50.1%
421:727
36.7:63.3%
<0.001
Table 1 Single drug resistance (non-Saudis vs. Saudis).
Non-Saudi Saudi p-Value All
No. % 994 (59.1%) 687 (40.9%) 1681
Streptomycin 98 (9.9%) 77 (11.2%) 0.47 175 (10.4%)
INH 97 (9.8%) 67 (9.8%) 1.0 164 (9.8%)
Rifampicin 14 (1.4%) 12 (1.7%) 0.58 26 (1.5%)
Ethambutol 13 (1.3%) 4 (0.6%) 0.171 17 (1.0%)
Pulm.:extra pulmonary 727:267
73.1:26.9%
421:266
61.3:38.7%
<0.001 1148:533
68.3:31.7%
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sis were similar with no significant difference (Ta-
ble 2). Multi-drug resistance tuberculosis (defined
as resistance to INH and rifampicin) was 1.4%
(n = 24).
4. Discussion
TB continues to be a major concern as a public
health problem throughout the world. On one
hand, TB has adverse economic and social bear-
ings on the individual and the society. On the
other hand, TB causes increased demand on
health care systems for the provision of expertise
and constant supply of treatment. The emergence
of HIV in 1981 had contributed to the increase in
the incidence of pulmonary tuberculosis world-
wide and the emergence of MDR-tuberculosis
[14]. Worldwide there are approximately 8 million
new cases and 3 million deaths from tuberculosis
each year [15].
NTBCP in Saudi Arabia was launched in phases in
1997 in collaboration with WHOs Eastern Mediter-
ranean regional office for Middle East. The goal
was to lower the incidence rate of smear positive
pulmonary tuberculosis to 1/100,000 population
among nationals by the year 2010 [16]. In Saudi
Arabia the incidence of pulmonary tuberculosis
declined from 30.5/100,000 in1987 to 10.2/
100,000 in 2002, while the incidence of extra-pul-
monary tuberculosis declined from 6.5/100,000 in
1987 to 4.3/100,000 in 2002 [16]. According to a re-
cent study from the Eastern province, the inci-
dence of culture positive tuberculosis per 100,000populations was 5.2 in 1989, 3.5 in 1993 and 7.6
in 2003, showing an increasing linear trend over
the study period [8]. In the same study, the rate
of resistance to any first-line agent was 28% [8].
There is a large variation in antituberculous drug
resistance between different countries, regions
and cities both worldwide and within countries. In
this context, knowledge of the susceptibility pat-
terns and prevalence of drug resistance in a given
area become essential to tailor initial intensive
phase therapy.
In the Kingdom of Saudi Arabia the resistance
rates to isoniazid alone vary from one region of
the country to another. This has been 3.4–19.4%
in Riyadh (central region) [7], 10.3–28.7% in Jed-
dah (western region) [17], 41% in Jizan (southern
region), 6.5% in Taif (southwest region) [7], and
6–12.5% in Dammam area [8,18]. In the current
study, isoniazid (1 lg/ml) resistance rate was
9.8% and is in line with the findings in previous
studies from the same region. Thus, empiric initial
intensive phase anti TB therapy should include four
drugs.
The second most common resistance pattern
noted in the study was streptomycin (10.4%).
Streptomycin resistance in Saudi Arabia has been
variable and reported figures are: 15.9% in Taif,
22.7% in Jeddah [7], 1–7% in Dammam area
[8,18], and 8.8% in Riyadh [19].
Resistance rate to rifampicin in the study was
1.5%, while previously reported rates in Dammam
area were 0.2–7.5% [8,18]. Thus, rifampicin resis-
tance rate falls within the previously reported
range. This range is lower than the rates of
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23.4%, Taif 15.3% and Jizan 20% [6].
According to the WHO report, the rate of MDR-
TB in Saudi Arabia is 3.4% [20]. However the rate
of MDR-TB in Saudi Arabia is variable depending
on the date of the study and region of the country,
as well as the proportion of non-Saudi population in
each study [7–10]. In Riyadh, MDR-TB ranged be-
tween 3.7% in 1979–1982 and 11.85% in 1986–
1988 [6]; on the other hand, a very high rate of
MDR-TB (44%) was reported from Jizan (southern
region) adjacent to Yemen [7]. In Dammam (East-
ern region) where this study took place, MDR-TB
rates previously reported were between 0.7% and
6% [8,18]; the rate of this range is consistent with
the rate of 1.4% in this study.
The variability in the resistance rates of tuber-
culosis in Saudi Arabia is dependent on multiple
factors as mentioned above [7–10]. However, no
significant difference in resistance rates were
found between Saudis and non-Saudi patients.
Many studies [6,16] from Saudi Arabia did not ad-
dress whether the site of isolation (pulmonary or
extra-pulmonary) of M. tuberculosis has any im-
pact on the resistance pattern. In a small but re-
cent study in the Eastern region, no difference
was shown in the resistance rates between pulmon-
ary and extra-pulmonary isolates [8]. Similarly in
the current study, there was no significant differ-
ence in drug resistance rates between those having
pulmonary or extra-pulmonary tuberculosis.
In conclusion, the pattern of anti-TB drug resis-
tance to first-line agents was examined in this
study over a period of 7 years. The resistance rates
to isoniazid, rifampicin and MDR-TB were low in
this area compared with other areas, but consis-
tent with the findings reported from the same area
of the Kingdom. Having a central reference Myco-
bacteriology laboratory would be ideal to monitor
the quality as well as uniformity of materials and
methods used in the culture and susceptibility test-
ing. Based on this study, the use of four anti-TB
therapies are required empirically to treat affected
patients.
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